 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...1112131415161718192021...212213» |
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: New Insights into the Cooperativity and Dynamics of Dimeric Enzymes. (Pubmed Central) - Aug 24, 2023
These advancements not only provide essential case studies and theoretical support for comprehending dimeric enzyme catalysis but also serve as a foundation for designing highly efficient catalysts, such as dimeric organic catalysts. Moreover, these developments have significant implications for drug design, as exemplified by Paxlovid, which was designed for the homodimeric main protease of SARS-CoV-2.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir. (Pubmed Central) - Aug 22, 2023
We report a new synthesis of nirmatrelvir featuring a highly enantioselective biocatalytic desymmetrization (>99% ee) and a highly diastereoselective multicomponent reaction (>25:1 dr) as the key steps. Our route avoids the use of transition metals and peptide coupling reagents, resulting in an overall highly efficient and atom-economic process.
- | Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal, Real-world evidence, Real-world: Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel. (Pubmed Central) - Aug 22, 2023
At 28 days post-MOV dispensation, the cumulative incidence (95% CI) of COVID-19-related hospitalization and/or all-cause mortality was 3.6% (2.5%, 4.6%), with similar rates across sexes and age groups (18-64 vs. ?65 years), and lower rates among recently vaccinated and/or recently SARS-CoV-2-infected patients. These data describe the characteristics and outcomes for MOV-treated patients in Israel, whose clinical characteristics may preclude the use of nirmatrelvir/ritonavir to treat their COVID-19 infection.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: SARS-CoV-2 Encephalitis versus Influenza Encephalitis: More Similarities than Differences. (Pubmed Central) - Aug 22, 2023
Both car-ry significant morbidity and mortality. Efficacious vaccines for prophylaxis and antivirals for treat-ment are available for both viruses.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Discovery and structure-activity relationship studies of novel ?-ketoamide derivatives targeting the SARS-CoV-2 main protease. (Pubmed Central) - Aug 22, 2023
Efficacious vaccines for prophylaxis and antivirals for treat-ment are available for both viruses. In an in vitro antiviral assay, 27h showed excellent activity with an EC value of 43.6
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors. (Pubmed Central) - Aug 22, 2023
SARS-CoV-2 main protease (M) is a validated antiviral drug target of nirmatrelvir, the active ingredient in Pfizer's oral drug Paxlovid...X-ray crystal structures of M with Jun10541R and Jun10221 revealed covalent modification of Cys145. These M inhibitors with diverse reactive warheads collectively represent promising candidates for further development.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Theoretical insights into the binding interaction of Nirmatrelvir with SARS-CoV-2 Mpro mutants (C145A and C145S): MD simulations and binding free-energy calculation to understand drug resistance. (Pubmed Central) - Aug 21, 2023
Moreover, PCA analysis confirms the detachment of the linker region from the major domains in C145S and C145A mutants allowing for conformational alterations in the active-site region. Based on the predicted biological activities and binding affinities of NMV to WT and mutant (C145A & C145S) M, it can be stipulated that NMV may have conventional potency to act as an anti-viral agent against WT M, while the catalytic-dyad mutations may show substantial mutation-induced drug resistance.Communicated by Ramaswamy H. Sarma.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Le nirmatrelvir-ritonavir pour les patients non hospitalis (Pubmed Central) - Aug 20, 2023
Based on the predicted biological activities and binding affinities of NMV to WT and mutant (C145A & C145S) M, it can be stipulated that NMV may have conventional potency to act as an anti-viral agent against WT M, while the catalytic-dyad mutations may show substantial mutation-induced drug resistance.Communicated by Ramaswamy H. Sarma. No abstract available
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19: Case-based approach to assessment and treatment. (Pubmed Central) - Aug 20, 2023
No abstract available No abstract available
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal, Monotherapy: Nirmatrelvir resistance - de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure - a case report. (Pubmed Central) - Aug 19, 2023
We describe an immunocompromised patient who was treated with repeated and prolonged courses of nirmatrelvir and developed de-novo E166V/L50F mutations in the Mpro region. These mutations were associates with clinical and virological treatment failure.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, azvudine (FNC) / Granlen
New trial: Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19 (clinicaltrials.gov) - Aug 18, 2023
P=N/A, N=1500, Not yet recruiting, Sponsor: Xiao Li?MD
- |||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
New trial: A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco (clinicaltrials.gov) - Aug 18, 2023
P=N/A, N=150, Not yet recruiting, Sponsor: Pfizer
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-World Effectiveness of Nirmatrelvir/Ritonavir and Dexamethasone Among Hospitalized Patients with COVID-19: A Prospective Cohort Study. (Pubmed Central) - Aug 17, 2023
Combination therapy of N/R and dexamethasone increased negative conversion of NAAT and was associated with a non-significant improvement in clinical recovery. Further studies are warranted to confirm this efficacy.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY. (Pubmed Central) - Aug 15, 2023
In high-risk patients with haematological malignancies and COVID-19, molnupiravir showed rates of hospitalization and mortality comparable to those of nirmatrelvir/ritonavir in this matched-pair analysis. Molnupiravir appears to be a plausible alternative to nirmatrelvir/ritonavir for COVID-19 treatment in patients with haematological malignancy.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects. (Pubmed Central) - Aug 15, 2023
We validated lapatinib-mediated inhibition of ErbB activity as an important mechanism of antiviral action. These findings reveal regulation of viral replication, inflammation, and tissue injury via ErbBs and establish a proof-of-principle for a repurposed, ErbB-targeted approach to combat emerging viruses.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses. (Pubmed Central) - Aug 15, 2023
Additionally, we find that pyronaridine additively combines with current COVID-19 treatments such as nirmatrelvir (protease inhibitor in Paxlovid) and molnupiravir to further inhibit SARS-CoV-2 infections. There are many antiviral compounds that demonstrate efficacy in cellular models, but few that show this level of impact in multiple mouse models and represent a promising therapeutic for the current coronavirus pandemic as well as future outbreaks as well.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS-COV-2 infection: A systematic review. (Pubmed Central) - Aug 14, 2023
Early use of Paxlovid in the older adult population with COVID-19 is beneficial. However, in the setting of limited resources, Paxlovid should be prioritised for older patients.
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Phase classification: Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). (clinicaltrials.gov) - Aug 14, 2023
P2/3, N=1440, Terminated, Sponsor: Pfizer
However, in the setting of limited resources, Paxlovid should be prioritised for older patients. Phase classification: P3 --> P2/3
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Deuteration for Metabolic Stabilization of SARS-CoV-2 Inhibitors GC373 and Nirmatrelvir. (Pubmed Central) - Aug 14, 2023
Hydrogens can be replaced with deuterium in nirmatrelvir and GC373 to slow oxidation. Results show that deuterium slows oxidation of nirmatrelvir adjacent to nitrogen by ?40% and that the type of warhead can switch the site of oxidative metabolism.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Upgrading nirmatrelvir to inhibit SARS-CoV-2 Mpro via DeepFrag and free energy calculations. (Pubmed Central) - Aug 14, 2023
However, the vdW term is the most important factor in controlling the ligand-binding affinity. In addition, the modified nirmatrelvir might be less toxic to the human body than the original inhibitor.
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
An Infectious Rise in Fats - Severe Hypertriglyceridemia Secondary to SARS-CoV-2 Infection (Zone 4, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_5829;
He was prescribed paxlovid and discharged home...Further research is needed to deduce how infectious processes can lead to elevated TG levels. Treatment consists of initiating a low-fat diet and may include fibrates.
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Retrospective data, Journal, Real-world evidence, Real-world: Real world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk COVID-19 patients during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study. (Pubmed Central) - Aug 12, 2023
Treatment consists of initiating a low-fat diet and may include fibrates. Nirmatrelvir-ritonavir treatment was associated with reduced hospitalization in high-risk COVID-19 patients even in highly vaccinated populations.
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients. (Pubmed Central) - Aug 11, 2023
Nirmatrelvir-ritonavir treatment was associated with reduced hospitalization in high-risk COVID-19 patients even in highly vaccinated populations. Collectively, these real-world findings suggest that although the risks of hospitalization and death due to COVID-19 have been reduced, antivirals can provide additional benefits to members of highly vulnerable patient populations.
- LB Abstract 2 TBD 3 (254 AB) - Aug 11, 2023 - Abstract #IDWeek2023IDWeek_431;
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Phase classification: EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease (clinicaltrials.gov) - Aug 9, 2023
P2/3, N=160, Recruiting, Sponsor: Pfizer
Collectively, these real-world findings suggest that although the risks of hospitalization and death due to COVID-19 have been reduced, antivirals can provide additional benefits to members of highly vulnerable patient populations. Phase classification: P3 --> P2/3
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study. (Pubmed Central) - Aug 7, 2023
Early initiation of nirmatrelvir plus ritonavir was associated for the first time with a significantly reduced risk of all-cause mortality by day 28 compared to molnupiravir, both in the overall population and in patient subgroups, including those fully vaccinated with the booster dose. This study did not receive funding.
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Anthracyclines inhibit SARS-CoV-2 infection. (Pubmed Central) - Aug 7, 2023
Six compounds were found to inhibit SARS-CoV-2 at the half maximal inhibitory concentration (IC50) below 1 ?M, including the anthracycline drug aclarubicin that markedly reduced viral RNA-dependent RNA polymerase (RdRp)-mediated gene expression, whereas other anthracyclines inhibited SARS-CoV-2 by activating the expression of interferon and antiviral genes. As the most commonly prescribed anti-cancer drugs, anthracyclines hold the promise of becoming new SARS-CoV-2 inhibitors.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment open: RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (clinicaltrials.gov) - Aug 7, 2023
P2, N=900, Enrolling by invitation, Sponsor: Kanecia Obie Zimmerman
As the most commonly prescribed anti-cancer drugs, anthracyclines hold the promise of becoming new SARS-CoV-2 inhibitors. Not yet recruiting --> Enrolling by invitation
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment open: RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (clinicaltrials.gov) - Aug 7, 2023
P2, N=900, Enrolling by invitation, Sponsor: Kanecia Obie Zimmerman
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Enrolling by invitation
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Journal: DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors. (Pubmed Central) - Aug 5, 2023
Furthermore, these compounds demonstrate efficacy against mutant forms of M that have shown resistance to the standard-of-care drug nirmatrelvir. Overall, this work demonstrates that DEC-Tec can efficiently generate novel and potent inhibitors without preliminary chemical or structural information.
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Journal: Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge. (Pubmed Central) - Aug 4, 2023
Overall, this work demonstrates that DEC-Tec can efficiently generate novel and potent inhibitors without preliminary chemical or structural information. No abstract available
- IF I MOVE, DOES IT EXPLODE? LUNG BULLAE IN INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ACUTE VIRAL PNEUMONIA (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_5068;
- Jakafi (ruxolitinib) / Novartis, Incyte, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
TUMOR LYSIS SYNDROME DUE TO CONCURRENT ADMINISTRATION OF PAXLOVID AND RUXOLITINIB (Convention Center Exhibit Hall - Rapid Area 1C) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3161;
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
PAXLOVID-ASSOCIATED STEVENS-JOHNSON SYNDROME (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3063;
- PRIMARY PULMONARY MUCOEPIDERMOID CARCINOMA: A POSSIBLE TRIGGER FROM CORONAVIRUS-19 INFECTION (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2419;
- GOOD C-OP, BAD C-OP? (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2184;
- A POST-COVID-19 ANOMALY: UNIQUE CASE OF THROMBOEMBOLISM STATUS-POST THROMBECTOMY IN A COVID-19 PATIENT (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2114;
- || Paxlovid (nirmatrelvir and ritonavir) / Pfizer
So sorry to hear that. Have you done Paxlovid? (Twitter) - Aug 3, 2023
- | Journal: Medication safety in chronic kidney disease. (Pubmed Central) - Aug 3, 2023
Several medications increase the risk of development of acute kidney injury or progression of CKD. Close attention is needed to select the appropriate dose or safer alternatives to reduce the risk of drug-induced harm in patients with CKD.
- ||| Paxlovid (nirmatrelvir and ritonavir) / Pfizer
You can’t take Paxlovid long term. Protease inhibitors are rough and Pax is god awful. Every single provider I have has nothing positive to say about it. I took it once and never again. I couldn’t tolerate it and it did absolutely nothing beneficial for me. (Twitter) - Aug 3, 2023
- ||| Paxlovid (nirmatrelvir and ritonavir) / Pfizer
6 weeks post 15 days paxlovid. Best thing I ever did. We tested everything, throughout my LC, interleukins, toxins, etc. My labs on 5th day of pax were impressive. Now we know, mild initial infection, lack of proper immune response to clear the virus. (Twitter) - Aug 3, 2023
- ||| Paxlovid (nirmatrelvir and ritonavir) / Pfizer
That's nonsense, it's a little hard on the kidneys, take supportive supps and you're ok through it. Long COVID was much harder on the organs then paxlovid was. (Twitter) - Aug 3, 2023
- |||| Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Clinical: But Paxlovid and vaccines do not prevent Long Covid. And what is Long Covid, anyway? How big is the iceberg? There’s been an attempt to define a list of conditions that may mean you have Long Covid, but that is just the tip of the iceberg. Time to look under the surface. /13 (Twitter) - Aug 3, 2023
- |||| Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Clinical: Fortunately for you, Jha says the important part out loud. “The only way to prevent Long Covid is to avoid catching Covid.” Vaccines may prevent some cases. Vaccines do not completely prevent Covid. Paxlovid exists, if you can get it, that is. If you can take it. If. /12 (Twitter) - Aug 3, 2023
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment closed: A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin (clinicaltrials.gov) - Aug 3, 2023
P1, N=12, Active, not recruiting, Sponsor: Pfizer
Close attention is needed to select the appropriate dose or safer alternatives to reduce the risk of drug-induced harm in patients with CKD. Recruiting --> Active, not recruiting
- |||| Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Clinical: I believe the real question is whether Paxlovid provides any benefit to the vaccinated or those with natural (partial) immunity acquired from prior infection. For some time, no studies could demonstrate this benefit. Has that changed? (Twitter) - Aug 2, 2023
- ||||| metformin / Generic mfg., Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Clinical, Interview: ICYMI , What drug is outperforming Paxlovid in treating long COVID? @MonicaGandhi9 discussed all things HIV, how it informed COVID, and rebuilding trust in healthcare. Watch the full interview: https://t.co/KK3br40qW4 #hiv #longcovid #metformin @HOPEforHIVCure (Twitter) - Aug 2, 2023
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal, Metastases: Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19). (Pubmed Central) - Aug 2, 2023
P
Nirmatrelvir-ritonavir should be considered for use in patients with CKD, including stage 5 CKD on dialysis. Clinical Trials Registration.?Clinical Trials.gov; identifier: NCT05624840.
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Preclinical, Journal: Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report. (Pubmed Central) - Aug 2, 2023
Remdesivir-nirmatrelvir combination has synergic activity in vitro. This combination may have a role in immunosuppressed patients with severe COVID-19 and prolonged viral shedding.
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Journal: Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study. (Pubmed Central) - Aug 2, 2023
This combination may have a role in immunosuppressed patients with severe COVID-19 and prolonged viral shedding. In our patient population of high-risk, mainly immunocompromised, vaccinated patients during the prevalence of the Omicron variant, NMV/r and 3RDV were equally effective early treatments for the prevention of hospitalization and/or death.